Chronic Kidney Disease

Chronic kidney disease progresses in complex ways; cell-therapy research focuses on slowing fibrosis.

Anti-fibrotic and anti-inflammatory effects studied in models.

Early-phase human safety studies exist.

Reported adverse events are mostly local — swelling, pain, or bruising at the harvest and injection sites. Infection and cell-processing quality remain the key risks to monitor.

Existing studies are limited by sample size, methodology, and follow-up, and SVF preparation differs substantially between centres, making cross-study comparison difficult.